Catherine M. Szyman - Sep 8, 2021 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role: CVP, Critical Care
Signature: Linda J. Park, Attorney-in-Fact
Stock symbol: EW
Transactions as of: Sep 8, 2021
Transactions value $: -$969,398
Form type: 4
Date filed: 9/8/2021, 09:04 PM
Previous filing: Aug 5, 2021
Next filing: Oct 18, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	EW	Common Stock	Options Exercise	$212K	+9.74K	+35.53%	$21.76	37.2K	Sep 8, 2021	Direct	F1
transaction	EW	Common Stock	Sale	-$1.18M	-9.74K	-26.22%	$121.28	27.4K	Sep 8, 2021	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	EW	Employee Stock Option (Right to Acquire)	Options Exercise	$0	-9.74K	-7.33%	$0.00	123K	Sep 8, 2021	Common Stock	9.74K	$21.76	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 4, 2021.
F2	This transaction was executed in multiple trades at prices ranging from $120.9950 to $121.7000. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.